Table 2.
Demographics and clinical characteristics
| Lupus clinical characteristics | |
| Disease duration | 9.4±6.4 |
| Age at diagnosis | 22.6±9.1 |
| SLE Disease Activity Index | 4.6±3.5 |
| SLICC | 0.7 (0.2-1.2) |
| Anti-dsDNA antibodies (mg/dL) | 123.7±106.3 |
| C3 complement (mg/dL) | 104.7±37.4 |
| C4 complement (mg/dL) | 24.3±13.8 |
| Urine creatinine (mg/dL) | 184 (132-236) |
| Urine protein (mg/dL) | 123 (85-161) |
| Urine protein/creatinine ratio | 0.5 (0.2-0.7) |
| White blood cell count | 4.9 (3.9-5.9) |
| Medications | |
| Hydroxychloroquine | 17 (68%) |
| Azathioprine | 6 (24%) |
| Methotrexate | 1 (4%) |
| Humira | 1 (4%) |
| Benlysta | 1 (4%) |
| Mycophenalate mofetil | 10 (40%) |
| Prednisone | 19 (76%) |
| General history | |
| Body mass index | 26±5 |
| Blood pressure | |
| Systolic (mmHg) | 121 (±18) |
| Diastolic (mmHg) | 73 (±14) |